KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.98

Nilotinib vs dasatinib in achieving MR4.5 for de novo chronic myeloid leukemia: the randomized JALSG CML212 study.

Itaru Matsumura, Shigeki Ohtake, Yoshiko Atsuta, Mio Kurata, Yosuke Minami, Naoto Takahashi, Chiaki Nakaseko, Noriyoshi Iriyama, Katsumichi Fujimaki, Kazuhiko Kakihana, Yoji Ogasawara, Takaaki Ono, Masaya Okada, Tetsuzo Tauchi, Toshihiro Miyamoto, Kazunori Ohnishi, Emiko Sakaida, Shin Fujisawa, Yukio Kobayashi, Norio Asou, Tomoki Naoe, Hitoshi Kiyoi, Yasushi Miyazaki

Blood Adv 8(20) 5237-5247

PMID38968156
PMCIDPMC11493191
DOI10.1182/bloodadvances.2024012655
发表日期2024-07-05
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:图像复核确认至少一个 KM 面板含可见 No. at risk 表。
摘要

摘要

Deep molecular response (DMR) is a prerequite for treatment-free remission (TFR) in chronic myeloid leukemia in chronic phase (CML-CP). The JALSG (Japan Adult Leukemia Study Group) conducted a prospective randomized phase 3 CML212 study for de novo CML-CP to compare the cumulative achievement of molecular response 4.5 (MR4.5; international scale BCR::ABL1 ≤0.0032%) by 18 months between nilotinib and dasatinib treatment as a primary end point. A total of 454 patients were randomly assigned to the 300 mg nilotinib twice daily arm or to the 100 mg dasatinib daily arm (both n = 227). BCR::ABL1 messenger RNA levels were monitored every 3 months. Study treatment was stopped if the patients were judged as failure according to the European LekemiaNet 2009 criteria or showed intolerance. The cumulative achievement rates of MR4.5 by 18 months were 32.6% (95% confidence interval [CI], 26.5-39.1) in the nilotinib arm and 30.8% (95% CI, 24.9-37.3) in the dasatinib arm with no significant difference (P = .66). The cumulative achievement rates of early molecular response, complete cytogenetic response, and major molecular response by 12, 18, 24, and 36 months were almost the same between the 2 arms. There was no significant difference in progression-free survival (PFS) or overall survival (OS) between the 2 arms by log-rank tests (PFS, P = .58; OS, P = .64). These results suggest that nilotinib and dasatinib would be equally effective for patients with de novo CML-CP. This trial was registered in the University Hospital Medical Information Network Clinical Trials Registry as #UMIN000007909.

KM 提取结果

3 个 Figure · 8 个 KM 面板

进入结果中心
KM Figure1 个面板

captionless-figure

Graphical abstract

Times_to_MR4.5_PP_

Times to MR4.5

captionless-figure · Panel Times_to_MR4.5_PP_

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel Times_to_MR4.5_PP_ 是同一 captionless-figure 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 2 条,实际恢复 1 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
KM Figure4 个面板

Figure 4

Figure 4. Comparison of times to cytogenetic and molecular responses between the nilotinib arm and the dasatinib arm. Times to the first CCyR (A), MMR (B), MR 4.0 (C), and MR 4.5 (D). Times to cytogenetic and molecular responses were defined as the intervals from the date of first dose to the response events and analyzed on the PP population by the cumulative incidence method with a Gray test. If the patients died or were lost to follow-up without achieving the events, these patients were treated as censored cases at the date of death or the last follow-up.

A

CCyR

Figure 4 · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 Figure 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 2:frequent upward jumps曲线 2:extreme upward reversal
查看结果
B

MMR

Figure 4 · Panel B

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel B 是同一 Figure 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线缺失:预期 2 条,实际恢复 1 条曲线 2:frequent upward jumps曲线 2:extreme jump曲线 2:extreme upward reversal
查看结果
C

MR4.0

Figure 4 · Panel C

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel C 是同一 Figure 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 2 条,实际恢复 1 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
D

MR4.5

Figure 4 · Panel D

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel D 是同一 Figure 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似图例或人工水平线:轨迹出现不合理的共同平台疑似图例或人工水平线:轨迹出现不合理的共同平台
查看结果
KM Figure3 个面板

Figure 5

Figure 5. Comparison of PFS, EFS, and OS between the nilotinib arm and the dasatinib arm. PFS (A), EFS (B), and OS (C). PFS, EFS, and OS were defined as the interval from the date of randomization until the date of progression or death from any causes, whichever came first (PFS); until the date of the earliest of defined events (EFS); and until the date of death from any causes (OS), respectively. PFS, EFS, and OS were analysis on the ITT population using the Kaplan-Meier method with a log-rank test.

A

PFS

Figure 5 · Panel A

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel A 是同一 Figure 5 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 2 条,实际恢复 1 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
B

EFS

Figure 5 · Panel B

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel B 是同一 Figure 5 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
C

OS

Figure 5 · Panel C

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel C 是同一 Figure 5 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线缺失:预期 2 条,实际恢复 1 条曲线 1:flat topline artifact曲线 2:off origin start曲线 2:extreme upward reversal
查看结果
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1. Flow diagram of the patients and analyzed population. ITT population consisted of all patients who were randomized. Safety population consisted of individuals who received at least 1 dose of the protocol treatment. PP population consisted of subjects who received at least 1 dose of the protocol treatment and excluded those who were determined to be ineligible for the study.
非 KM Figure
Figure 2Figure 2. Comparison of MR4.5 and EMR between the nilotinib arm and the dasatinib arm. Cumulative achievement rates of MR 4.5 (A) and achievement rates of EMR (B). The results were calculated on the ITT population by means of the Cochran-Mantel-Haenszel (CMH) test.
非 KM Figure
Figure 3Figure 3. Comparison of cytogenetic and molecular responses between the nilotinib arm and the dasatinib arm. Cumulative achievement rates of CCyR (A), MMR (B), MR 4.0 (C), and MR 4.5 (D) by 12, 18, 24, and 36 months. The results were calculated on the ITT population by means of the CMH test. ∗Primary end point and same as Figure 2B.
非 KM Figure